Replimune’s RP1+nivolumab melanoma BLA faces an FDA decision by Apr 10, 2026. The current cash runway extends to Q1'27. See ...

AI has made it easier than ever for anyone to post faux content on Reddit, even as execs argue that it's one of the most authentic corners of the web.

Former Manchester United midfielder Owen Hargreaves has explained the tactical change implemented by caretaker manager ...

This tiny, inexpensive microcontroller makes it easy to build reliable, room-by-room Home Assistant sensors without paying the smart home tax.

Google DeepMind has been tinkering with Lyria for a while now, offering limited access in developer-oriented products like ...

We’re entering a new renaissance of software development. We should all be excited, despite the uncertainties that lie ahead.

In Minneapolis, videos of the Alex Pretti killing undermined the federal government’s account. But an A.I. video of Brad Pitt shows the dangers ahead.

A new variation of the fake recruiter campaign from North Korean threat actors is targeting JavaScript and Python developers ...

The consensus price target hints at a 65.7% upside potential for Replimune Group (REPL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.

Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.

The coming months are set to define Replimune's trajectory. The FDA's decision on RP1 in April 2026 will establish the immediate commercial path, while the RP2 data expected later that same year will ...